US Stock MarketDetailed Quotes
BDRX Biodexa Pharmaceuticals
- 1.3200
- -0.1900-12.58%
Close May 1 16:00 ET
- 1.3100
- -0.0100-0.76%
Post 19:26 ET
5.79MMarket Cap-131P/E (TTM)
1.5000High1.2200Low640.13KVolume1.4500Open1.5100Pre Close876.42KTurnover21.47%Turnover RatioLossP/E (Static)4.38MShares20.800052wk High0.99P/B3.94MFloat Cap0.670052wk Low--Dividend TTM2.98MShs Float587200.0000Historical High--Div YieldTTM18.54%Amplitude0.6700Historical Low1.3690Avg Price1Lot Size
Biodexa Pharmaceuticals Stock Forum
Sign in to post a comment
$Biodexa Pharmaceuticals(BDRX.US$
They just might let this one go.... in one month after they beat it down again.
They just might let this one go.... in one month after they beat it down again.
$Biodexa Pharmaceuticals(BDRX.US$
NEWS (late)
Biodexa’s Licensor Emtora to Announce Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis to be Presented at Prestigious 2024 Digestive Disease Week Annual Meeting
Biodexa Pharmaceuticals PLC, through its licensor Emtora Biosciences, will present the Phase 2 clinical trial results of eRapa in Familial Adenomatous Polyposis at the 2024 Digestive Disease Week Annual Meeting. The presentation is set for May 18-21, 2024, in Washin...
NEWS (late)
Biodexa’s Licensor Emtora to Announce Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis to be Presented at Prestigious 2024 Digestive Disease Week Annual Meeting
Biodexa Pharmaceuticals PLC, through its licensor Emtora Biosciences, will present the Phase 2 clinical trial results of eRapa in Familial Adenomatous Polyposis at the 2024 Digestive Disease Week Annual Meeting. The presentation is set for May 18-21, 2024, in Washin...
2
$Biodexa Pharmaceuticals(BDRX.US$
pleased to announce that's its licensor Emtora Biosciences has announced that results of a Phase 2 clinical trial of eRapa in Familial Adenomatous Polyposis ("FAP") are to be presented at the prestigious 2024 Digestive Disease Week annual meeting in Washington DC on May 18-21, 2024.
pleased to announce that's its licensor Emtora Biosciences has announced that results of a Phase 2 clinical trial of eRapa in Familial Adenomatous Polyposis ("FAP") are to be presented at the prestigious 2024 Digestive Disease Week annual meeting in Washington DC on May 18-21, 2024.
1
$Biodexa Pharmaceuticals(BDRX.US$ I wonder what excitement we will have today... bullish 🫰🎆📈
1
$Biodexa Pharmaceuticals(BDRX.US$ accidentally bought 2700 shares phuhk hope it pumps monday, n e one know what time this stock opens pre market, i know pre is at 4 but this stock usually seems to open at different times on pre
1
2
$Biodexa Pharmaceuticals(BDRX.US$ with today's performance it makes me need to take some pharmaceuticals lol
No comment yet
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
I Am 102927471 :